Answers are grounded in this paper and cite their sources.
Case report shows stabilization of an inoperable pseudotumor in hemophilia A, indicating the benefit of emicizumab therapy.
Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under‐resourced setting.
No takes yet. Share an insight, caveat, or question.
Kilach et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: